Some hairstylists have confirmed an uptick in clients who complain about losing hair while on weight-loss journeys.

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

People using Ozempic say they are losing their desire to drink. It’s anecdotal evidence right now, but this would be a game-changer for those who are trying to break free from addiction.

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Angus King (I-Maine) today introduced the End Prescription Drug Ads Now Act, legislation that would ban prescription drug advertising on television, radio, print, digital platforms and social media.

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

The major averages posted modest gains on Thursday, catching a tailwind from a cooler-than-anticipated inflation report.